@inproceedings{inproceedings, title  = {{A phase IIa study of amlitelimab, a novel nondepleting anti-OX40Ligand mAb in patients with moderate to severe atopic dermatitis}},

 url = {{}},

 year = {{2022}},

 month = {{1}},

 author = {{Weidinger S and Cork M and Reich A and Beiber T and Gilbert S and Brennan N and Wilson R and Quaratino S and Porter-Brown B}},

 volume = {{187}},

 journal = {{BRITISH JOURNAL OF DERMATOLOGY}},

 issue = {{3}},

 pages = {{E96-E96}},

 note = {{Accessed on 2024/12/22}}}